Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Mallinckrodt
Merck
Boehringer Ingelheim
Medtronic

Last Updated: February 3, 2023

CLINICAL TRIALS PROFILE FOR ZOLINZA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Zolinza

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00121225 ↗ Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma Completed National Cancer Institute (NCI) Phase 2 2005-09-01 This phase II trial is studying how well vorinostat works in treating patients with metastatic or unresectable melanoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
NCT00127101 ↗ An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED) Terminated Merck Sharp & Dohme Corp. Phase 1 2005-09-01 This is an investigational study that increases the dosage to determine the safety/tolerability, and efficacy of a histone deacetylase inhibitor in combination with Targretin in patients with cutaneous T-cell lymphoma in patients who have failed at least one prior systemic therapy.
NCT00128102 ↗ Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) Completed Merck Sharp & Dohme Corp. Phase 3 2005-06-30 The goal of this study is to assess the efficacy and safety of an oral investigational drug suberoylanilide hydroxamic acid (vorinostat, MK-0683) compared to placebo, in the treatment of participants with advanced malignant pleural mesothelioma who have failed at least one prior chemotherapy regimen. The primary hypotheses are the following: (1) vorinostat improves overall survival (OS) compared to placebo (2) vorinostat is generally safe and well tolerated.
NCT00132002 ↗ Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer Terminated National Cancer Institute (NCI) Phase 2 2005-06-01 This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with progressive stage IV breast cancer. Drugs used in chemotherapy, such as suberoylanilide hydroxamic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Suberoylanilide hydroxamic acid may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zolinza

Condition Name

Condition Name for Zolinza
Intervention Trials
Lymphoma 11
Unspecified Adult Solid Tumor, Protocol Specific 10
Recurrent Adult Acute Myeloid Leukemia 10
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zolinza
Intervention Trials
Lymphoma 35
Leukemia 26
Lymphoma, Non-Hodgkin 21
Leukemia, Myeloid, Acute 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zolinza

Trials by Country

Trials by Country for Zolinza
Location Trials
United States 545
Canada 33
Australia 8
Japan 6
Germany 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zolinza
Location Trials
Texas 43
California 35
Pennsylvania 30
New York 27
Maryland 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zolinza

Clinical Trial Phase

Clinical Trial Phase for Zolinza
Clinical Trial Phase Trials
Phase 3 3
Phase 2/Phase 3 2
Phase 2 53
[disabled in preview] 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zolinza
Clinical Trial Phase Trials
Completed 91
Terminated 30
Active, not recruiting 21
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zolinza

Sponsor Name

Sponsor Name for Zolinza
Sponsor Trials
National Cancer Institute (NCI) 81
Merck Sharp & Dohme Corp. 39
M.D. Anderson Cancer Center 19
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zolinza
Sponsor Trials
Other 165
NIH 86
Industry 63
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Harvard Business School
Colorcon
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.